SORT BY

FILTER BY

also on other fortune lists

company facts

g500 stats

Global 500

Chris Ratcliffe — Bloomberg via Getty Images

173

Pfizer

PFE

U.S.

Pfizer landed one of 2016’s most sought-after biopharma deals with its $14 billion acquisition of cancer drug maker Medivation, beating out the likes of Sanofi. In another critical business decision, the firm announced last fall that it wouldn’t split into two publicly traded companies in order to separate its generic and branded pharmaceutical businesses, raising the prospect of even more future deals. Pfizer also came under fire over drug price increases–including a record $107 million fine by U.K. regulators for hiking an epilepsy treatment’s price by 2,600%.

Looking for leads, investment insights, or competitive intelligence?

CEO

Ian C. Read

Sector

Health Care

Industry

Pharmaceuticals

HQ Location

New York, NY

Years on Global 500 List

23

Employees

96,500

Pfizer is also featured in these fortune lists
Key Financials (Last Fiscal Year)
($ Millions)% change
Revenues ($M)$52,8248.1%
Profits ($M)$7,215.03.7%
Assets ($M)$171,615
Total Stockholder Equity ($M)$59,544
Profit Ratios
Profit as % of Revenues13.7%
Profits as % of Assets4.2%
Profits as % of Stockholder Equity12.1%
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Pfizer

Healthcare Stocks Soar After McCain Rejects Obamacare Repeal

The Graham Cassidy bill appears dead, but the stock market has found new life.

Read More →
The FDA Just Approved a New Pfizer Cancer Drug for a Rare, Vicious Leukemia

The therapy, Besponsa, treats a rapidly progressing version of the disease.

Read More →
Why Martin Shkreli Won’t Be the Last Pharma Bro

Price gouging isn’t going away anytime soon.

Read More →